Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1997 1
2001 1
2002 1
2004 3
2008 2
2010 1
2011 2
2012 1
2013 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. Eslin D, et al. Int J Cancer. 2023 Sep 1;153(5):1026-1034. doi: 10.1002/ijc.34569. Epub 2023 May 29. Int J Cancer. 2023. PMID: 37246577 Clinical Trial.
All patients received Nfx (30 mg/kg/day divided TID daily), Topotecan (0.75 mg/m(2) /dose, days 1-5) and Cyclophosphamide (250 mg/m(2) /dose, days 1-5) every 3 weeks. ...In stratum 3, there was a 20% response rate and a 65% total benefit rate, an average time on therapy of …
All patients received Nfx (30 mg/kg/day divided TID daily), Topotecan (0.75 mg/m(2) /dose, days 1-5) and Cyclophosphamide (250 mg/m(2 …
The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease.
Schutt SD, Wu Y, Kharel A, Bastian D, Choi HJ, Hanief Sofi M, Mealer C, McDaniel Mims B, Nguyen H, Liu C, Helke K, Cui W, Zhang X, Ben-David Y, Yu XZ. Schutt SD, et al. J Clin Invest. 2022 Nov 1;132(21):e143950. doi: 10.1172/JCI143950. J Clin Invest. 2022. PMID: 36074578 Free PMC article.
Fli-1 promoted the transcription of Th1/Th17 pathways and T cell receptor-inducible (TCR-inducible) transcription factors in CD4+ T cells, while suppressing activation- and function-related gene pathways in CD8+ T cells. Importantly, a low dose of camptothecin, topoteca …
Fli-1 promoted the transcription of Th1/Th17 pathways and T cell receptor-inducible (TCR-inducible) transcription factors in CD4+ T cells, w …
Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan.
Ozan H, Ozkalemkas F, Ozan U, Ozerkan K, Bilgin T, Küçükyildiz F. Ozan H, et al. Eur J Gynaecol Oncol. 2001;22(6):463-5. Eur J Gynaecol Oncol. 2001. PMID: 11874084
PURPOSE: To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of topotecan-related myeloid suppression. METHODS: No medication was given to 21 rats in group 1; 1.5 mg/m2/day topotecan w …
PURPOSE: To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of …
Topotecan treatment and its toxic effects on hematologic parameters and trace elements.
Bülbül Hizel S, Sanli C, Bayar Muluk N, Albayrak M, Ozyazici A, Apan A. Bülbül Hizel S, et al. Biol Trace Elem Res. 2008 Aug;124(2):129-34. doi: 10.1007/s12011-008-8140-9. Epub 2008 May 23. Biol Trace Elem Res. 2008. PMID: 18498005
The study was conducted on three groups consisting of 16 and 18 rabbits in the study groups and 15 rabbits in the control group. Rabbits in group I (n = 16) received high-dose topotecan intravenously (i.v.; 0.5 mg/kg once daily), while rabbits in group II (n = 18) received …
The study was conducted on three groups consisting of 16 and 18 rabbits in the study groups and 15 rabbits in the control group. Rabbits in …
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R. Kretschmar CS, et al. J Clin Oncol. 2004 Oct 15;22(20):4119-26. doi: 10.1200/JCO.2004.08.174. J Clin Oncol. 2004. PMID: 15483021 Clinical Trial.
PURPOSE: Most children older than 1 year of age with metastatic neuroblastoma (NB) die despite intensive chemotherapy and bone marrow transplantation. The Pediatric Oncology Group conducted a study of paclitaxel, topotecan, and topotecan-cyclophosphami …
PURPOSE: Most children older than 1 year of age with metastatic neuroblastoma (NB) die despite intensive chemotherapy and bone mar …
Role of weekly paclitaxel in the treatment of advanced ovarian cancer.
Thomas H, Rosenberg P. Thomas H, et al. Crit Rev Oncol Hematol. 2002 Dec 27;44 Suppl:S43-51. doi: 10.1016/s1040-8428(02)00103-8. Crit Rev Oncol Hematol. 2002. PMID: 12505598 Review.
The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard paclitaxel 3-weekly administration. ...Such therapy has included weekly paclitaxel in combination wit …
The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and oth …
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.
Dose reduction of topotecan was used for severe bone marrow suppression. Peritoneal (topotecan) and plasma (topotecan and etoposide) levels were assessed at multiple time points using high-pressure liquid chromatography. ...Additional stu …
Dose reduction of topotecan was used for severe bone marrow suppression. Peritoneal (topotecan) and plasm …
Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan.
Bakheet SA. Bakheet SA. Oxid Med Cell Longev. 2011;2011:824597. doi: 10.1155/2011/824597. Epub 2011 Aug 15. Oxid Med Cell Longev. 2011. PMID: 21904648 Free PMC article.
Quercetin was neither cytotoxic nor genotoxic in mice at doses tested. Pretreatment of mice with quercetin significantly reduced topotecan-induced genotoxicity and cytotoxicity in bone marrow cells, and these effects were dose dependent. ...Based on the data …
Quercetin was neither cytotoxic nor genotoxic in mice at doses tested. Pretreatment of mice with quercetin significantly reduced topoteca …
[Therapeutic and adverse effects of topotecan combined with cisplatin for treatment of advanced squamous cell lung cancer and head and neck cancer].
Xiang Y, Li QY, Shao JH, Yang JZ. Xiang Y, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Mar;28(3):491-3. Nan Fang Yi Ke Da Xue Xue Bao. 2008. PMID: 18359722 Chinese.
OBJECTIVE: To evaluate the therapeutic and adverse effects of topotecan combined with cisplatin in the treatment of advanced squamous cell lung cancer and head and neck cancer. ...The total response rate was 48.4% among the patients, with the median survival time of 10.1 m …
OBJECTIVE: To evaluate the therapeutic and adverse effects of topotecan combined with cisplatin in the treatment of advanced squamous …
[Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells].
Li J, Law HK, Liu YL, Chan GC. Li J, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):991-6. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010. PMID: 20723315 Chinese.
Mesenchymal stem cells (MSC) are important cellular component of the bone marrow microenvironment in supporting hemopoiesis. Li J et al reported previously that MSCs are resistant to chemotherapy commonly used in hematologic malignancies but are relatively sensitive …
Mesenchymal stem cells (MSC) are important cellular component of the bone marrow microenvironment in supporting hemopoiesis. L …
16 results